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| INTRODUC TI ON
Activated fibroblasts surrounding cancer cells, known as CAFs, are the main component of cancer stroma and play a critical role in tumor progression. 1, 2 Cancer-associated fibroblasts secrete diverse growth factors, chemokines, and cytokines including TGF-β or VEGF and accelerate the proliferation of cancer cells directly or indirectly. [3] [4] [5] Alteration of TP53 gene expression has been observed in cancer stroma, [6] [7] [8] and TP53-suppressed fibroblasts can promote tumor growth by accelerating the secretion of cytokines or growth factors, in addition to accelerating fibroblast proliferation. 9 Cancer-associated fibroblasts can be considered a promising target for antitumor therapy due to their roles in cancer progression. However, the mechanism by which cells transition from normal tissue fibroblasts to CAFs remains unclear.
The TP53 gene is a crucial tumor suppressor, and its mutational inactivation is observed at a high frequency in all human cancers. 10, 11 TP53 is a transcription factor that regulates the expression of genes associated with cell cycle arrest, apoptosis, and senescence. In addition, recent studies suggest that TP53 gene expression acts in a non-cell-autonomous fashion and can affect the cellular microenvironment. The functional loss of TP53 in cancer cells activates JAK2-STAT3 signaling and promotes modification of the tumor stroma and subsequent tumor growth. 12 In addition, we previously reported that functional deficiency of TP53 in cancer cells can promote fibroblast-mediated angiogenesis and tumor growth. 13 Significant changes in the secretion levels of a large number of proteins 14, 15 and the production of reactive oxygen species 12, 13 have been reported as mechanisms by which a cancer cell can affect its surroundings through the alteration of TP53 expression. TP53 expression might also affect surrounding stromal cells by modifying the secretion of miRNAs sequestered in exosomes. Although the exact molecular mechanisms of miRNA recruitment into exosomes are not well understood, 16 it is known that changes in TP53 expression in a cancer cell can alter the miRNA profile in CDEs. 17 Such changes in miRNA levels have been reported to mediate macrophage repolarization.
17
However, to the best of our knowledge, their impact on fibroblast modification has not been reported.
We posited that diverse factors can influence fibroblast modification in the tumor microenvironment; among these, CDEs play a role in fibroblast modification and fibroblast-mediated tumor growth related to TP53 deficiency in cancer cells. Our goal in this study was to elucidate the role of exosomes derived from TP53-deficient cancer cells in fibroblast-mediated tumor growth.
| MATERIAL S AND ME THODS

| Cell culture
The human colon cancer cell line HCT116 showing WT TP53 expression, HT29 TP53 mutant cells, nontransformed human colon fibroblasts CCD-18Co, and WI-38 human lung fibroblasts were obtained from ATCC. All cell lines used more than 2 years after purchase were authenticated to verify their identity and lack of contamination (National Institute of Biomedical Innovation, Osaka, Japan 
| Exosome isolation
Prior to collection of the culture medium, the cancer cells were washed with PBS, and the medium was switched to fresh serumfree DMEM. After incubation for 48 hours, the conditioned medium was collected, and sequential centrifugation was carried out. The medium was first centrifuged at 300 g for 10 minutes and then at 2000 g for 10 minutes to precipitate the cells. The supernatant was centrifuged at 10 000 g for 30 minutes and then ultracentrifuged at 100 000 g for 70 minutes to pellet extracellular vesicles, which were then washed by suspension in PBS. These vesicles were then ultracentrifuged at 100 000 g for 70 minutes. The final pellet was resuspended in 100 μL PBS. The protein yield was measured using a bicinchoninic acid protein assay kit (Thermo Fisher Scientific).
The morphology of exosomes was observed using transmission electron microscopy (H-7600; Hitachi High-Technologies) after preparation as described here. Approximately 5 μL of sample was placed on Parafilm (Bemis Company, Neenah, WI, USA). Then, a carbon-coated 400 mesh copper grid was positioned on top of the drop for 10 seconds and washed by a droplet of distilled water. The grid was contrasted by adding a drop of 2% uranyl acetate on Parafilm and incubating the grid on top of the drop for 10 seconds. Excess liquid was removed by gently using an absorbent paper. After drying, the samples were used for observation.
Other materials and methods are described in Appendix S1 and Tables S1,S2. All animal protocols of this study were approved by and CCD-18Co cells were also significantly bigger than those of HCT116 sh control and CCD-18Co cells ( Figure 1E ,F).
| Exosomes derived from TP53-inactivated cancer cells promoted fibroblast-mediated tumor growth
We next examined the role of CDEs in fibroblast modification. We confirmed that there was no significant difference in the protein levels of isolated pellets from the supernatant of HCT116
sh control and HCT116 sh p53 cells and that the isolated particles expressed the representative markers for exosomes: Hsp70, Alix, and tetraspanins (CD9, CD63, and CD81) ( Figure 2A ). Transmission electron microscopy showed the morphology of exosomes ( Figure 2B ). The distribution of the particle size and particle number (concentration) of the isolated particles from the culture supernatants of HCT116 sh control and HCT116 sh p53 cells was characterized using a NanoSight instrument (Malvern Panalytical). The diameter of the isolated particles from both cell lines revealed exosomes of typical size (approximately 100 nm), and no significant difference was seen in either particle size or particle number (concentration) from HCT116 sh control vs HCT116 sh p53 cells ( Figure S1 ). To ascertain the role of CDEs in tumor growth, we analyzed the effect of exosome inhibition using siRNA targeting RAB27A
( Figures 2E and S3 ), a regulator of exosome secretion and member of the RAS oncogene family. 18 We evaluated the protein levels of the exosome-associated protein CD9 in isolated pellets obtained from culture media supernatants of HCT116 sh control and 
| Exosomes derived from TP53-inactivated cancer cells suppressed TP53 expression in fibroblasts
To determine the effect of CDEs, we stimulated the fibroblasts with HCT116 sh control -or HCT116 sh p53 -derived exosomes. Contrary to the phenotypic changes observed in the coculture experiments summarized in Figure 1C , the expression levels of TGF-β1 and VEGFA in CCD-18Co cells were not increased by HCT116 sh p53 -derived exosomes as compared with HCT116 sh control -derived exosomes.
However, TP53 expression in CCD-18Co cells was significantly decreased by HCT116 sh p53 -exosomes, which is consistent with the results of the coculture experiments ( Figure 3A ,B). In addition, CCD-18Co cells incubated with HCT116 sh p53 -derived exosomes showed significantly increased proliferation compared to CCD-18Co alone or CCD-18Co incubated with HCT116 sh control -derived exosomes ( Figure 3C ). Therefore, we hypothesized that TP53-deficient cancer cells inhibited TP53 expression in fibroblasts and accelerated fibroblast proliferation by altering their exosomal contents. However, the expression of TGF-β1 and VEGFA might be increased by factors other than exosomes. Thus, we focused on the decreased expression of TP53, as a target gene of exosomes derived from p53-deficient cancer cells. To investigate the impact of TP53 inhibition in fibroblasts on tumor growth, we targeted TP53 expression in CCD-18Co cells using siRNA ( Figure 3D ). The proliferation of CCD-18Co cells was significantly increased following TP53 suppression ( Figure 3E ).
In addition, coculture with TP53-suppressed CCD-18Co cells en- (Table S3 ). Ten of these 51 miRNAs were not detected in either the HCT116 sh control -or HCT116 sh p53 -derived exosomes, and 4 of 51 were exclusively detected in HCT116 sh p53 -derived exosomes ( Figure S5 ). We then compared the expression of the 37 miRNAs remaining after excluding the 14 miRNAs present in both HCT116 sh control -and HCT116 sh p53 -derived exosomes ( Figure 4D ). Thirty-one of 37 miRNAs showed higher expression in HCT116 sh p53 -derived exosomes compared with HCT116 sh control -derived exosomes. In contrast, only 6 miRNAs showed a higher expression in HCT116 sh control -derived exosomes. Figure 5E ). We next introduced specific inhibitors for the 3 miRNAs into CCD-18Co cells, and the expression of miR-1249-5p, miR-6737-5p, and miR-6819-5p was successfully downregulated by using a specific inhibitor for each miRNA in CCD-18Co cells ( Figure 5F ). With the mixture of the 3 miRNA inhibitors, both TP53 and its downstream target CDKN1A were significantly upregulated ( Figure 5G ).
F I G U R E 2 Exosomes derived from TP53-inactivated cancer cells contributed to fibroblast
| Exosomes derived from TP53-mutant cancer cells modified fibroblasts to promote tumor growth
We utilized HT29 TP53-mutant cancer cells to further ascertain the role of TP53 in cancer cells in fibroblast-mediated tumor growth.
The proliferation of CCD-18Co cells was increased when cocultured 
, miR-6737-5p, and miR-6819-5p suppressed TP53 expression in fibroblasts. A, Three miRNAs targeting TP53, which predicted that the 3′-UTR of TP53 is a direct target of miR-1249-5p, miR-6737-5p, and miR-6819-5p. B, Relative expression levels of miR-1249-5p, miR-6737-5p, and miR-6819-5p in HCT116 sh control -or HCT116 sh p53 -derived exosomes using quantitative RT-PCR (qRT-PCR); *P < 0.05 vs HCT116 sh control -derived exosomes. C, Relative expression levels of miR-1249-5p, miR-6737-5p, and miR-6819-5p in HCT116 sh control and HCT116 sh p53 cells vs RNU6B as an internal control, evaluated by qRT-PCR; *P < 0.05 vs HCT116 sh control .
D, Relative expression of TP53 in CCD-18Co cells with or without miRNA mimics of miR-1249-5p, 6737-5p, or 6819-5p; *P < 0.05 using qRT-PCR and western blotting. E, Relative TP53 expression in CCD-18Co cells with or without scrambled miRNA mimics of the 3 miRNAs, assayed using qRT-PCR and western blotting; *P < 0.01. F, Relative expression of intracellular miRNAs (miR-1249-5p, miR-6737-5p, and miR-6819-5p) with specific miRNA inhibitors for miR-1249-5p, 6737-5p or 6819-5p determined by qRT-PCR using RNU6B as an internal control; *P < 0.05 vs CCD-18Co cells without inhibitor (negative control [N/C]). G, Relative expression of TP53 and CDKN1A in CCD-18Co cells with or without miRNA inhibitors, determined using qRT-PCR; *P < 0.05 and **P < 0.01 vs negative control CCD-18Co cells (N/C) with HT29 cells (Figure 6A ). This result was consistent with that using HCT116 sh p53 cells.
Next, we stimulated the fibroblasts with HT29-derived exosomes, which also significantly accelerated the proliferation of CCD-18Co cells ( Figure 6B ). The TP53 and P21 expression levels of CCD-18Co cells were significantly suppressed by HT29-derived exosomes ( Figure 6C ). When CCD-18Co cells were cocultured with HT29 cells in which the expression of RAB27A was suppressed, the proliferation of HT29 cells, as well as fibroblasts, was significantly inhibited ( Figure 6D,E) .
We investigated the role of miR-1249-5p, miR-6737-5p, and miR-6819-5p in mediating the enhancement of CCD-18Co cell proliferation by HT29 cells. The expression levels of these 3 miRNAs were higher in exosomes derived from HT29 cells than from TP53-WT HCT116 cells ( Figure S6 ). When we introduced inhibitors for these 3 miRNAs into CCD-18Co cells, the proliferation of these cells was significantly inhibited in the presence of HT29 cells ( Figure 6F ). These results suggest that exosomes derived from TP53-mutant HT29 cancer cells modify fibroblasts in a similar fashion as those from HCT116 sh p53 cells. Our research has revealed a novel regulator of fibroblast modification related to cross-talk among cancer cells in the tumor microenvironment. We propose that specific miRNAs in CDEs could play an essential role in stroma-mediated tumor growth and that targeting such miRNAs could represent a possible therapeutic strategy. 
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